Association of Serum Myostatin with Body Weight, Visceral Fat Volume, and High Sensitivity C-Reactive Protein But Not With Muscle Mass and Physical Fitness in Premenopausal Women

 

 Permissions and Reprints

Abstract

Background The myokine myostatin regulates muscle mass and has been linked to insulin resistance and metabolic syndrome. However, data on its role in humans is still limited. We, therefore, investigated the associations of serum myostatin with muscle mass, physical fitness, and components of the metabolic syndrome in a cohort of premenopausal women.

Methods We undertook a cross-sectional analysis of 233 women from the monocenter study PPSDiab, conducted in Munich, Germany. Participants had recently completed a pregnancy with or without gestational diabetes. Our analysis included medical history, anthropometrics, oral glucose tolerance testing, laboratory chemistry, cardiopulmonary exercise testing, and magnetic resonance imaging (n=142) of visceral fat volume, left quadriceps muscle mass, and muscle fat content. Serum myostatin was quantified by a competitive enzyme-linked immunosorbent assay.

Results We observed positive correlations of serum myostatin with body mass index (ρ=0.235; p=0.0003), body fat percentage (ρ=0.166; p=0.011), waist circumference (ρ=0.206; p=0.002), intraabdominal fat volume (ρ=0.182; p=0.030) and high-sensitivity C-reactive protein (ρ=0.175; p=0.008). These correlations were reproduced in linear regression analyses with adjustment for age and time after delivery. We saw no correlations with muscle mass, physical fitness, insulin sensitivity, triglycerides, HDL cholesterol, and blood pressure.

Conclusions Our observation of elevated serum myostatin in women with a higher body fat percentage, visceral obesity, and elevated c-reactive protein suggests that this myokine contributes to the altered muscle-adipose tissue crosstalk in metabolic syndrome. Elevated myostatin may advance this pathophysiologic process and could also impair the efficacy of exercise interventions. Further mechanistic studies, therefore, seem warranted.

Publication History

Received: 29 January 2021
Received: 15 April 2021

Article published online:
18 August 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• References

• 1 McPherron AC, Lawler AM, Lee S-J. Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member. Nature 1997; 387: 83-90 doi:10.1038/387083a0
  CrossrefPubMedGoogle Scholar
• 2 McPherron AC. Metabolic functions of myostatin and GDF11. Immunol Endocr Metab Agents Med Chem 2010; 10: 217-231 doi:10.2174/187152210793663810
  CrossrefPubMedGoogle Scholar
• 3 Allen DL, Cleary AS, Speaker KJ. et al. Myostatin, activin receptor IIb, and follistatin-like-3 gene expression are altered in adipose tissue and skeletal muscle of obese mice. Am J Physiol Endocrinol Metab 2008; 294: E918-E927 doi:10.1152/ajpendo.00798.2007
  CrossrefPubMedGoogle Scholar
• 4 Lin J, Arnold HB, Della-Fera MA. et al. Myostatin knockout in mice increases myogenesis and decreases adipogenesis. Biochem Biophys Res Commun 2002; 291: 701-706 doi:10.1006/bbrc.2002.6500
  CrossrefPubMedGoogle Scholar
• 5 Schuelke M, Wagner KR, Stolz LE. et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 2004; 350: 2682-2688 doi:10.1056/NEJMoa040933
  CrossrefPubMedGoogle Scholar
• 6 Delanaye P, Bataille S, Quinonez K. et al. Myostatin and insulin-like growth factor 1 are biomarkers of muscle strength, muscle mass, and mortality in patients on hemodialysis. J Ren Nutr 2019; 29: 511-520 doi:10.1053/j.jrn.2018.11.010
  CrossrefPubMedGoogle Scholar
• 7 Esposito P, Battaglia Y, La Porta E. et al. Significance of serum myostatin in hemodialysis patients. BMC Nephrol 2019; 20: 462 doi:10.1186/s12882-019-1647-9
  CrossrefPubMedGoogle Scholar
• 8 Carvalho LP, Basso-Vanelli RP, Di Thommazo-Luporini L. et al. Myostatin and adipokines: The role of the metabolically unhealthy obese phenotype in muscle function and aerobic capacity in young adults. Cytokine 2018; 107: 118-124 doi:10.1016/j.cyto.2017.12.008
  CrossrefPubMedGoogle Scholar
• 9 Amor M, Itariu BK, Moreno-Viedma V. et al. Serum myostatin is upregulated in obesity and correlates with insulin resistance in humans. Exp Clin Endocrinol Diabetes 2018; DOI: 10.1055/a-0641-5546.
  Article in Thieme ConnectPubMedGoogle Scholar
• 10 Hittel DS, Axelson M, Sarna N. et al. Myostatin decreases with aerobic exercise and associates with insulin resistance. Med Sci Sports Exerc 2010; 42: 2023-2029 doi:10.1249/MSS.0b013e3181e0b9a8
  CrossrefPubMedGoogle Scholar
• 11 Brandt C, Nielsen AR, Fischer CP. et al. Plasma and muscle myostatin in relation to type 2 diabetes. PloS one 2012; 7: e37236 doi:10.1371/journal.pone.0037236
  CrossrefPubMedGoogle Scholar
• 12 Feig DS, Zinman B, Wang X. et al. Risk of development of diabetes mellitus after diagnosis of gestational diabetes. Can Med Assoc J 2008; 179: 229-234 doi:10.1503/cmaj.080012
  CrossrefPubMedGoogle Scholar
• 13 Gar C, Rottenkolber M, Grallert H. et al. Physical fitness and plasma leptin in women with recent gestational diabetes. PLoS One 2017; 12: e0179128 doi:10.1371/journal.pone.0179128
  CrossrefPubMedGoogle Scholar
• 14 Roth SM, Walsh S. Myostatin: a therapeutic target for skeletal muscle wasting. Curr Opin Clin Nutr Metab Care 2004; 7: 259-263 doi:10.1097/00075197-200405000-00004
  CrossrefPubMedGoogle Scholar
• 15 Chen MJ, Han DS, Yang JH. et al. Myostatin and its association with abdominal obesity, androgen and follistatin levels in women with polycystic ovary syndrome. Hum Reprod 2012; 27: 2476-2483 doi:10.1093/humrep/des209
  CrossrefPubMedGoogle Scholar
• 16 Hittel DS, Berggren JR, Shearer J. et al. Increased secretion and expression of myostatin in skeletal muscle from extremely obese women. Diabetes 2009; 58: 30-38 doi:10.2337/db08-0943
  CrossrefPubMedGoogle Scholar
• 17 Rottenkolber M, Ferrari U, Holland L. et al. The diabetes risk phenotype of young women with recent gestational diabetes. J Clin Endocrinol Metab 2015; 100: E910-E918 doi:10.1210/jc.2014-3898
  CrossrefPubMedGoogle Scholar
• 18 Metzger BE, Gabbe SG, Persson B. et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010; 33: 676-682 doi: 10.2337/dc09-1848
  CrossrefPubMedGoogle Scholar
• 19 Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470
  CrossrefPubMedGoogle Scholar
• 20 Wintgens KF, Dschietzig T, Stoeva S. et al. Plasma myostatin measured by a competitive ELISA using a highly specific antiserum. Clin Chim Acta 2012; 413: 1288-1294 doi:10.1016/j.cca.2012.04.023
  CrossrefPubMedGoogle Scholar
• 21 Pons C, Borotikar B, Garetier M. et al. Quantifying skeletal muscle volume and shape in humans using MRI: A systematic review of validity and reliability. PloS one 2018; 13: e0207847 doi:10.1371/journal.pone.0207847
  CrossrefPubMedGoogle Scholar
• 22 Hogrel JY, Barnouin Y, Azzabou N. et al. NMR imaging estimates of muscle volume and intramuscular fat infiltration in the thigh: Variations with muscle, gender, and age. Age (Dordr) 2015; 37: 9798 doi:10.1007/s11357-015-9798-5
  CrossrefPubMedGoogle Scholar
• 23 Mersmann F, Bohm S, Schroll A. et al. Muscle shape consistency and muscle volume prediction of thigh muscles. Scand J Med Sci Sports 2015; 25: e208-e213 doi: 10.1111/sms.12285
  CrossrefPubMedGoogle Scholar
• 24 Torriani M, Thomas BJ, Halpern EF. et al. Intramyocellular lipid quantification: repeatability with 1H MR spectroscopy. Radiology 2005; 236: 609-614 doi:10.1148/radiol.2362041661
  CrossrefPubMedGoogle Scholar
• 25 Dong J, Dong Y, Dong Y. et al. Inhibition of myostatin in mice improves insulin sensitivity via irisin-mediated cross talk between muscle and adipose tissues. Int J Obes (Lond) 2016; 40: 434-442 doi:10.1038/ijo.2015.200
  CrossrefPubMedGoogle Scholar
• 26 Nesto RW. Obesity: a major component of the metabolic syndrome. Tex Heart Inst J 2005; 32: 387-389
  PubMedGoogle Scholar
• 27 Rodríguez A, Becerril S, Ezquerro S. et al. Crosstalk between adipokines and myokines in fat browning. Acta Physiol (Oxf) 2017; 219: 362-381 doi: 10.1111/apha.12686
  CrossrefPubMedGoogle Scholar
• 28 Assyov YS, Velikova TV, Kamenov ZA. Myostatin and carbohydrate disturbances. Endocr Res 2017; 42: 102-109 doi:10.1080/07435800.2016.1198802
  CrossrefPubMedGoogle Scholar
• 29 Matsakas A, Foster K, Otto A. et al. Molecular, cellular and physiological investigation of myostatin propeptide-mediated muscle growth in adult mice. Neuromuscul Disord 2009; 19: 489-499 doi:10.1016/j.nmd.2009.06.367
  CrossrefPubMedGoogle Scholar
• 30 Zhu X, Hadhazy M, Wehling M. et al. Dominant negative myostatin produces hypertrophy without hyperplasia in muscle. FEBS Lett 2000; 474: 71-75 doi:10.1016/s0014-5793(00)01570-2
  CrossrefPubMedGoogle Scholar
• 31 Reisz-Porszasz S, Bhasin S, Artaza JN. et al. Lower skeletal muscle mass in male transgenic mice with muscle-specific overexpression of myostatin. Am J Physiol Endocrinol Metab 2003; 285: E876-E888 doi:10.1152/ajpendo.00107.2003
  CrossrefPubMedGoogle Scholar
• 32 Lakshman KM, Bhasin S, Corcoran C. et al. Measurement of myostatin concentrations in human serum: Circulating concentrations in young and older men and effects of testosterone administration. Mol Cell Endocrinol 2009; 302: 26-32 doi:10.1016/j.mce.2008.12.019
  CrossrefPubMedGoogle Scholar
• 33 Zimmers TA, Davies MV, Koniaris LG. et al. Induction of cachexia in mice by systemically administered myostatin. Science 2002; 296: 1486-1488 doi:10.1126/science.1069525
  CrossrefPubMedGoogle Scholar

• Supplementary Material